1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : BIOTECHNOLOGY
  4. ADVANCED ENZYME TECHNOLOGIES LTD.
Advanced Enzyme Technologies Ltd.
NSE: ADVENZYMES | BSE: 540025

Advanced Enzyme Live Share Price Today, Share Analysis and Chart

Mid-range Performer
aboutAdvanced Enzyme Technologies Ltd. (AETL) is a research-driven company operating in the global enzyme and probiotics industry. It is the largest Indian enzyme company and ranks as the second-largest listed integrated enzyme player globally. The compan... Read More
Clinical TrialsPatent Approvals
Ask AI about Advanced Enzyme
263.55-0.60(-0.23%)

New 52W Low in past week

188.2K
NSE+BSE Volume

NSE 30 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Loading...
- / 100
- / 100
38.2 / 100
Mid-range PerformerThese stocks have strong quality. Their reasonable financials and technicals make them potentially attractive to investorsView SimilarEmbed DVM
Analyst Price Target
-

16

S

7

W

2

O

1

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

High rank

17Positive6Negative

Pass in checklist73.9%

045
55
100

PE Valuation Check

Right Now
Undervalued
66.2%
1 Year Forward
Undervalued
68.8%
INSIGHTAdvanced Enzyme is undervalued at both current PE and future earnings estimates.

Advanced Enzyme Stock Price Analysis

Day Price Range

-0.2% 1 Day return
263.6 (LTP)
259.5268
LowHigh

Week Price Range

6.1% 1 Week return
263.6 (LTP)
246.8268
LowHigh

Month Price Range

-6.4% 1 Month return
263.6 (LTP)
246.8281
LowHigh

52 Week Price Range

-14.4% 1 Year return
263.6 (LTP)
246.8419
LowHigh
View full Price History/Seasonality

Advanced Enzyme Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Inline

Advanced Enzyme 's Revenue was higher than average estimate 1 time in past 2 years

EPS forecast

CURRENT EPS
15.1
AVG. ESTIMATE
15.5
LOW ESTIMATE
15.5
HIGH ESTIMATE
15.5
CURRENT EPS
AVG. ESTIMATE
Hit

EPS is expected to grow by 2.9% in FY27

Consensus Recommendation

1 ANALYST Recommendations
STRONG BUY

The consensus recommendation from 1 analyst for Advanced Enzyme is STRONG BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Advanced Enzyme Technical Analysis

Advanced Enzyme EMA & SMA

Bearish-2
3 bullish, 5 bearish
Bullish3
Bearish5
5 Day261.3
10 Day261.4
12 Day262.1
20 Day265.9
26 Day269.1
50 Day280.7
100 Day295.6
200 Day306.5

Advanced Enzyme Delivery And Volume

Daily Avg. Delivery Volume %
30 Oct, 202658.7%
Week52.0%
Month56.6%
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Advanced Enzyme Resistance and Support

263.70
Pivot
First Resistance267.9
Second Resistance272.3
Third Resistance276.5
First Support259.4
Second Support255.2
Third Support250.8
Day RSI43.2
Day MACD-7
Day MFI49.5
Day MACD Signal Line-8.2

Advanced Enzyme Beta

1 Month0.7
1 Year1.0
3 Month0.8
3 Year0.9

Advanced Enzyme Price Change Analysis

↓-6.4%
Over 1 Month
LowHigh
246.8281
↓-16.4%
Over 3 Months
LowHigh
246.8343
↓-24.2%
Over 6 Months
LowHigh
246.8419
↓-14.5%
Over 1 Year
LowHigh
246.8419
All Technicals →

Advanced Enzyme Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Vasant RathiPromoter29,871,70226.9 %
Orbimed Asia Iii Mauritius Fvci LimitedFii13,509,52212.2 %
Pradip Bhailal ShahPublic1,857,4001.7 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Advanced Enzyme Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
GRAVITON RESEARCH CAPITAL LLPBulkSell29 Aug 2025352.611,007,488NSE
POLUNIN EMERGING MARKETS SMALL CAP FUND LLCBulkPurchase29 Aug 2025353.501,250,938NSE
GRAVITON RESEARCH CAPITAL LLPBulkPurchase29 Aug 2025352.131,007,488NSE
GRAVITON RESEARCH CAPITAL LLPBulkSell11 Sep 2024507.35821,877NSE
GRAVITON RESEARCH CAPITAL LLPBulkPurchase11 Sep 2024507.08821,877NSE
ORBIMED ASIA III MAURITIUS LIMITEDBlockSell19 Jun 202438511,053,245NSE
MOTILAL OSWAL FINANCIAL SERVICES LIMITEDBlockPurchase19 Jun 202438511,053,245NSE
ORBIMED ASIA III MAURITIUS LIMITEDBulkSell19 Jun 202438511,053,245NSE
MOTILAL OSWAL FINANCIAL SERVICES LIMITEDBulkPurchase19 Jun 202438511,053,245NSE
GRAVITON RESEARCH CAPITAL LLPBulkSell06 Dec 2023358.11723,134NSE
All deals
All insider trades

Advanced Enzyme Corporate Actions

Advanced Enzyme Dividend history and yield

Advanced Enzyme dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Advanced Enzyme dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
124 Jul 2026
1.35FINAL24 Jul 2026Equity Share
223 Jul 2025
1.2FINAL23 Jul 2025Equity Share
316 May 2025
4INTERIM17 May 2025Equity Share
418 Jul 2024
1.1FINAL18 Jul 2024Equity Share
517 May 2024
4INTERIM18 May 2024Equity Share

Advanced Enzyme Board Meetings

Advanced Enzyme past and upcoming board meetings.

#Ex-Date
PurposeNotes
131 Oct 2026
Quarterly Results-
208 Aug 2026
Quarterly Results & Buy Back-
309 May 2026
Audited Results & Dividend-
431 Jan 2026
Quarterly Results-
512 Nov 2025
Quarterly Results-

Advanced Enzyme Stock Split

Advanced Enzyme stock split details, including announcement, record, and ex-split dates, along with the split ratios

#Ex-Date
Old FVNew FVRecord Date
125 May 2017
10226 May 2017
All Corporate Actions

Advanced Enzyme Research Reports

Advanced Enzyme research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
116 May 2024ICICI Direct
Reco
Target
470373.75Buy25.75%-29.48%pdf
217 May 2023ICICI Direct
Target
310277.95Hold11.53%-5.18%pdf
321 Nov 2022ICICI Direct
Reco
Target
300273.05Hold9.87%-3.48%pdf
407 Aug 2022ICICI Direct
Reco
Target
265278.8Sell-4.95%-5.47%pdf
523 May 2022ICICI Direct290279.95Hold3.59%-5.86%pdf
All Reports of Advanced

Advanced Enzyme Corporate Filings

Advanced Enzyme BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
31 Oct 2026
Advanced Enzyme Technologies Ltd - 540025 - Announcement under Regulation 30 (LODR)-Post Buyback Public Announcement
Please find enclosed herewith Post Buyback Public Announcement.
PDF
31 Oct 2026
Advanced Enzyme Technologies Ltd - 540025 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find enclosed herewith Earnings Presentation for quarter and half year ended September 30, 2026.
PDF
31 Oct 2026
Advanced Enzyme Technologies Ltd - 540025 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed herewith press release titled Quarterly Earnings Release dated October 31, 2026.
PDF
31 Oct 2026
Advanced Enzyme Technologies Ltd - 540025 - Announcement under Regulation 31A (LODR)-(8)(b) Outcome of Board Meeting
The Board of Directors at their meeting held today i.e. October 31, 2026 have analysed the request received from the Promoter Group members for their reclassification from promoter group category to public category shareholders, pursuant to Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
PDF
31 Oct 2026
Advanced Enzyme Technologies Ltd - 540025 - Unaudited Financial Results (Standalone & Consolidated) Of The Company For The Quarter And Half Year Ended September 30, 2026
Advanced enzyme Technologies Limited has informed the exchange about the unaudited financial results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2026.
PDF
VIEW ALL

Advanced Enzyme DocumentsAsk MarketMind AI

Advanced Enzyme Earnings Call

Advanced Enzyme earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
18 Aug 2026Advanced Enzyme Technologies Ltd - 540025 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
12 Aug 2026Advanced Enzyme Technologies Ltd - 540025 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
15 May 2026Advanced Enzyme Technologies Ltd - 540025 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
12 May 2026Advanced Enzyme Technologies Results Earnings Call for Q4FY26 & Full YearAudioVideo
07 Feb 2026Advanced Enzyme Technologies Ltd - 540025 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
view all

Advanced Enzyme Annual Reports

Advanced Enzyme financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link
2023Annual Report Mar-2023Link
2022Annual Report Mar-2022Link

Advanced Enzyme Credit Ratings

Advanced Enzyme credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
29 Apr 2026crisil ratingsAdvanced Enzyme Technologies LimitedAdvanced Enzyme Technologies Limited:Ratings reaffirmed at 'Crisil A+ / Stable / Crisil A1+ 'Link
12 Feb 2026icra ratingsADVANCED ENZYME TECHNOLOGIES LIMITED[ICRA]AA- (Stable)/[ICRA]A1+; assignedLink
29 Jan 2025crisil ratingsAdvanced Enzyme Technologies LimitedAdvanced Enzyme Technologies Limited:Short-term rating upgraded to \u2018Crisil A1+\u2019; Long-term rating reaffirmedLink
27 Dec 2023crisil ratingsAdvanced Enzyme Technologies LimitedAdvanced Enzyme Technologies Limited:Ratings reaffirmed at 'CRISIL A+/Stable/CRISIL A1'Link
30 Oct 2022crisil ratingsAdvanced Enzyme Technologies LimitedAdvanced Enzyme Technologies Limited:Ratings reaffirmedLink

Advanced Enzyme Investor Presentations

Advanced Enzyme investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
31 Oct 2026Advanced Enzyme Technologies Ltd - 540025 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
08 Aug 2026Advanced Enzyme Technologies Ltd - 540025 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
09 May 2026Advanced Enzyme Technologies Ltd - 540025 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
31 Jan 2026Advanced Enzyme Technologies Ltd - 540025 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
12 Nov 2025Advanced Enzyme Technologies Ltd - 540025 - Announcement under Regulation 30 (LODR)-Investor PresentationLink

Advanced Enzyme - Company Profile

Advanced Enzyme Management Structure

Advanced Enzyme management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Mr. Beni Prasad RaukaChief Financial Officer-Mar 26
Sanjay BasantaniCompany Secretary,Compliance Officer,Head(Legal.)-Mar 26
Mr. Harshad DoshiChief Financial Officer,Chief Operating Officer-Mar 26
Ms. Martina DoeringManaging Director,Head(Business Development)-Mar 26
Dr. Michael PulsManaging Director,Head(Research & Development)-Mar 26
Mr. Satish PagarPlant Manager,Head(Operations)-Mar 26
Mr. Pradeep BhosalePlant Manager-Mar 26

Advanced Enzyme Board of Directors

Advanced Enzyme Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
MUKUND MADHUSUDAN KABRAE D & Wholetime Director352.19Mar 26
Vilas Murlidhar AurangabadkarIndependent Non Exe. Director18.1Mar 26
Pramod KasatIndependent Non Exe. Director16.5Mar 26
VASANT RATHIChairman & Non Executive Dir.15.7Mar 26
NITIN JAGANNATH DESHMUKHIndependent Non Exe. Director11.8Mar 26
Rasika RathiNon-Exec & Non-Independent Dir7.8Mar 26
Sunny SharmaNon-Exec & Non-Independent Dir3.9Mar 26
VandanaIndependent Non Exe. Director-Mar 26
PRADIP BHAILAL SHAHIndependent Director-Mar 26
Sanjay BasantaniCS / Compliance Officer / Legal Head-Mar 26
Website: www.advancedenzymes.com

About the company - Business Profile

Advanced Enzyme Technologies Ltd. (AETL) is a research-driven company operating in the global enzyme and probiotics industry. It is the largest Indian enzyme company and ranks as the second-largest listed integrated enzyme player globally. The company operates across the entire value chain, including research and development, commercial-scale manufacturing, and global marketing. AETL provides over 400 proprietary products developed from 68+ enzymes and probiotics, serving more than 700 customers across 45+ countries. Its offerings cater to human nutrition, animal nutrition, and industrial bio-processing sectors.

Key Points

Key Facts

  • Founded Year: 1989 (Incorporated as Advanced Biochemicals Pvt Ltd.)
  • Headquarters: Thane, Maharashtra, India.
  • Stock Listing: Listed on NSE (ADVENZYMES) and BSE (540025).
  • Market Capitalization: Approximately ₹33,830 million (as of December 2025).

Operations and Resources

  • Facilities: Operates 9 manufacturing facilities and 7 R&D centers.
  • Capacity: Total fermentation capacity exceeds 500 cubic meters.
  • Integration: Fully integrated model covering microbial technology, process scale-up, and application development.
  • IP Portfolio: Holds 17 patents (filed and granted) and has filed 15 Food Enzyme Dossiers with EFSA.

Privatization and Ownership

  • Promoter Holding: 43.04% (as of December 2025).
  • Institutional Holding: 31.16%, with major investors including OrbiMed Asia III Mauritius (12.07%) and Nalanda India Equity Fund (8.46%).
  • Public Holding: 25.80%.

Revenue Breakdown (FY 2024-25)

  • By Segment:
    • Human Nutrition: 66% (₹4,185 million), primarily enzymes and probiotics for healthcare.
    • Animal Nutrition: 11% (₹677 million), catering to poultry, ruminant, and pet food markets.
    • Industrial Bio-Processing: 15% (₹962 million), focusing on baking, textiles, and other industrial applications.
    • Specialized Manufacturing: 8% (₹539 million).
  • By Geography:
    • India: 50%
    • USA: 34%
    • Europe: 6%
    • Asia (ex-India): 7%
    • Rest of World: 3%

Key Products and Technology

  • Human Nutrition: Specialized enzymes and probiotics like ImmunoSEB and ProbioSEB CSC3 (which received NIH grants).
  • Baking Solutions: Clean-label enzymes designed to extend shelf life and improve texture, targeting markets in Europe and the Americas.
  • Biocatalysis: Developing enzymes for API manufacturers to reduce chemical usage and energy costs.
  • Technology: Proprietary fermentation and microbial technology for enzyme discovery and customization.

Employee and Human Capital

  • Total Workforce: 750+ employees globally (as of March 2025).
  • Diversity: Women comprise approximately 24.75% of the workforce.
  • Attrition: Reported employee turnover rate of 9.29% for FY 2024-25.

Current Strategic Initiatives and Outlook

  • Global Expansion: Focus on expanding presence in the baking industry within Europe and the Americas.
  • Product Pipeline: Currently conducting advanced trials for biocatalysis products with API manufacturers.
  • Regulatory Focus: Actively pursuing EFSA and US FDA evaluations, with 9 positive R&D opinions received for food enzyme dossiers.
  • Financial Performance (FY 2024-25): Consolidated revenue reached ₹6,369 million with an EBITDA margin of 31% and a PAT margin of 21%.

References

  1. Annual Report May 2024
  2. Annual Report May 2025
  3. Investor Presentation Nov 2025
  4. Investor Presentation Jan 2026

Advanced Enzyme FAQ

Advanced Enzyme today is trading in the red, down by 0.23% at ₹263.55.
Advanced Enzyme is currently trading down 0.23% on an intraday basis. In the past week the stock rose 6.12%. Stock has been down 16.36% in the past quarter and fell 14.45% in the past year. You can view this in the share price history/seasonality section.
Advanced Enzyme is listed on NSE with the ticker ADVENZYMES and on BSE as 540025. It's currently trading on NSE at a share price of ₹263.55 and on BSE with a share price of ₹262.95.
The market cap of Advanced Enzyme is ₹2,951.13 Cr. as of Oct 30, 2026.
Advanced Enzyme announced a FINAL dividend of 67.5% which equals ₹1.35 in Jul 24, 2026.The last three ex-dates for Advanced Enzyme were Jul 23, 2025, May 16, 2025 and Jul 18, 2024. To view the full dividend history of Advanced Enzyme click here.
Advanced Enzyme has never issued bonus shares, but it has issued 1 stock split since its BSE/NSE listing. The latest announcement for Advanced Enzyme stock split was on May 25, 2017 at a ratio of 10:2.
Advanced Enzyme reported ₹223.23 Cr. in revenue, ₹48.31 Cr. in net profit, and ₹80.84 Cr. in EBITD as of Oct 31, 2026 for Q2 FY26-27.
According to the prediction of 1 analyst, the share price prediction for Advanced Enzyme is ₹370 with an upside of 40%.
The PE ratio of Advanced Enzyme is 17.27 as of Oct 30, 2026.
The PB ratio of Advanced Enzyme is 1.77 as of Oct 30, 2026.
There are no analyst reports for Advanced Enzyme .
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×